Summer Symposium 2005

The New Science of Cancer Therapy

June 24, 2005

Targeting the Hedgehog Pathway in Cancer

Philip A. Beachy, HHMI/ The Johns Hopkins University School of Medicine

Gleevec as a Paradigm of Targeted Cancer Therapies

Brian Drucker, HHMI/ Oregon Health & Science University Cancer Institute

Molecular Targeted Therapy of Lung Cancer

Daniel Haber, Massachusetts General Hospital

Targeted Therapy Becomes a Clinical Reality

Susan Hellmann, Genentech, Inc.

Targeted Therapy: from Bench to Bedside

Pearl Huang, GlaxoSmithKline

VHL Tumor Suppressor Protein: Insights into Oxygen Sensing and Kidney Cancer

William Kaelin, Dana-Farber Cancer Institute

Cancer Drug Delivery

Robert Langer, Massachusetts Institute of Technology

Therapeutic Targets in the Ras Pathway

Frank McCormick, USCF Comprehensive Cancer Center

Progress in the Development of Histone Deacetylase Inhibitors

Victoria Richon, Merck & Co., Inc.

How Did We Get Here?

Robert Weinberg, Whitehead Institute, MIT